SomaLogic (SomaLogic) Accounts Receivable : $20.73 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SomaLogic Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. SomaLogic's accounts receivables for the quarter that ended in Sep. 2023 was $20.73 Mil.

Accounts receivable can be measured by Days Sales Outstanding. SomaLogic's Days Sales Outstanding for the quarter that ended in Sep. 2023 was 85.80.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. SomaLogic's Net-Net Working Capital per share for the quarter that ended in Sep. 2023 was $2.16.

SomaLogic Accounts Receivable Historical Data

The historical data trend for SomaLogic's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomaLogic Accounts Receivable Chart

SomaLogic Annual Data

Trend

Dec20

Dec21

Dec22

Accounts Receivable

17.45

17.07

17.01

SomaLogic Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Accounts Receivable	Get a 7-Day Free Trial								25.05	17.01	25.59	21.75	20.73

SomaLogic Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

SomaLogic Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

SomaLogic's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	20.73	/	22.048	*	91
=	85.80

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), SomaLogic's accounts receivable are only considered to be worth 75% of book value:

SomaLogic's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(453.81	+	0.75 * 20.73	+	0.5 * 13.884	-	68.309
-	0	-	0)	/	188.662
=	2.16

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

SomaLogic Accounts Receivable Related Terms

Thank you for viewing the detailed overview of SomaLogic's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

SomaLogic (SomaLogic) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SomaLogic Inc (NAS:SLGC) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

2945 Wilderness Place, Boulder, CO, USA, 80301

Website

https://www.somalogic.com

SomaLogic is a commercial-stage proteomics company. It operates as a protein biomarker discovery and clinical diagnostics company that develops slow off-rate modified aptamers, which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The Somamers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.

Executives

Alison Marie Roelke	officer: Chief People Officer	900 INNOVATORS WAY, SIMI VALLEY CA 93065
Adam Taich	officer: Interim CEO	C/O SOMALOGIC, INC., 2945 WILDERNESS PLACE, BOULDER CO 80301
Ruben Gutierrez	officer: General Counsel	6435 AVENIDA WILFREDO, LA JOLLA CA 92037
Kathy L Hibbs	director	C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
Jason Ryan	director	C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas D. Carey	director	8 PAIGE STREET, HINGHAM MA 02043
Eliot M Lurier	officer: Interim CFO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Tycho Peterson	director	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
Eli Casdin	director	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Shaun M. Blakeman	officer: Chief Financial Officer	C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Anne H. Margulies	director	C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Richard A Post	director	998 LACOSTA LANE, LANE TREE CO 80124
Charles M. Lillis	director	13 CASTLE PINES DRIVE N, CASTLE ROCK CO 80108
Stephen Quake	director	C/O FLUIDIGM CORPORATION, 7000 SHORELINE COURT, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Robert Barchi	director